Invitris GTM brain

Invitris develops cell-free biomanufacturing technology for organizations developing individualized protein medicines and antimicrobials.

category

Cell-free biomanufacturing for biologics

market profile

  • text: Invitris targets the gap between rapid computational protein design and physical manufacturing of many individualized variants.
  • text: An independent report describes a cell-free phage platform and paid proofs of concept, while noting that no named customer or clinical trial was public at publication.
  • text: Its original phage focus sits alongside a broader manufacturing ambition covering protein therapies and on-demand production.

personas

  • title: Head of biologics process development
    pains:
    • Conventional production economics and process transfers can be difficult for small individualized batches.
    • Needs reproducible yield, purity and quality data before selecting a new manufacturing platform.
  • title: AI protein design or discovery platform leader
    pains:
    • Computational candidate generation can outpace physical production and testing.
    • Slow design-test cycles limit how many candidates can be validated.
  • title: Antimicrobial therapeutics development lead
    pains:
    • Pathogen variation and resistance complicate development of targeted treatments.
    • Individualized candidates need a credible path from early proof of concept to clinical-quality production.

icp

  • text: Biotech and pharmaceutical developers building protein-based therapeutics or AI-designed candidates; company size thresholds are not publicly specified.
  • text: Antimicrobial and phage therapy programs seeking partners for tailored candidate production and development.
  • text: Potential partners evaluating decentralized and on-demand biomanufacturing, subject to validation of Invitris Pods and regulatory readiness.

message pillars

  • text: Compress the path from digital sequence to physical product.
  • text: Connect computational design and experimental feedback.
  • text: Use one platform across discovery and production scales.

objections

  • objection: Is the platform ready for our regulatory and quality requirements?
    response: Request program-specific validation, quality documentation and evidence of actual GMP readiness; marketing claims do not establish approval.
  • objection: Will the claimed time and economics apply to our molecule?
    response: Scope a proof of concept with agreed yield, purity, timing and cost measures rather than extrapolating site-wide claims.
  • objection: Can it support the protein class and scale we need?
    response: Ask for direct data on comparable candidates and the practical path from early screening to the required production volume.

competitors

  • name: Locus Biosciences
    website: https://www.locus-bio.com/platforms/
    why: Develops engineered phage therapeutics using its own platform and manufacturing, overlapping in antimicrobial programs.
  • name: Swiftscale Biologics
    why: Works on cell-free biomanufacturing for biologics, an alternative approach to faster production.
  • name: Acteryon
    why: Works on phage discovery and production optimization for an adjacent phage technology market.

influencers

  • name: Kilian Vogele
    url: https://www.linkedin.com/posts/invitris_phagetherapy-bacteriophage-amr-activity-7477775907210854400-J4kI
    why: Co-founder and CTO discusses cell-free phage production with the research community.
  • name: Michael Jewett
    url: https://invitris.com/
    why: Scientific advisor to Invitris and a researcher in cell-free bioengineering.

keywords

  • cell free protein manufacturing
  • individualized biologics manufacturing
  • phage manufacturing
  • AI drug manufacturing
  • cell free protein synthesis
  • on demand biomanufacturing
  • phage therapy development

voice

  • scientific
  • ambitious
  • manufacturing focused

signals

  • text: A biologics team is scaling AI-designed protein candidates and needs faster experimental validation.
  • text: An antimicrobial developer is investigating individualized phage therapy or a new manufacturing partner.

stack

  • cell-free protein synthesis
  • microfluidics

hiring

  • R&D Working Student, Martinsried
  • R&D Internship, Martinsried

pricing

model: unknown

motion

sales_led

channels

  • scientific conferences
  • LinkedIn
  • research partnerships
  • website inquiries

confidence

medium

Founders

  • name: Patrick Grossmann
    title: Founder
    role: Founder
    bio: My hearts are entrepreneurship & science, originally trained as bioinformatician at the Harvard Medical School and ETH Zurich amongst other schools. I earned a PhD and MBA, and highly enjoy opportunities to improve the world with science-based products. I co-founded Invitris to radically simplify drug development to stop antibiotic-resistance, which has the potential to become the dominating health-economic challenge in this century.
  • name: Kilian Vogele
    title: Founder
    role: Founder
    bio: Kilian, the CTO and co-founder of Invitris, is responsible for driving innovation and development within the company. With a PhD in synthetic biology from TUM and a track record of 5 patents, his expertise has been instrumental in creating Invitris' groundbreaking technology.

Back to YC companies